Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Acute kidney injury in cirrhosis.Hepatology. 2008; 48: 2064-2077
- A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis.J Hepatol. 2013; 59: 474-481
- Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites.J Hepatol. 2013; 59: 482-489
- Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.Hepatology. 1996; 23: 164-176
- Assessing renal function in cirrhotic patients: Problems and pitfalls.Am J Kidney Dis. 2003; 41: 269-278
- Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.Crit Care. 2004; 8: R204-R212
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.Crit Care. 2007; 11: R31
- Summary of recommendation Statements.Kidney Int Suppl. 2012; 2: 8-12
- Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.Gut. 2015; 64: 531-537
- News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document.J Hepatol. 2019; 71: 811-822
- K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis. 2002; 39: S1-S266
- The evolving concept of acute kidney injury in patients with cirrhosis.Nat Rev Gastroenterol Hepatol. 2015; 12: 711-719
- Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.Hepatology. 1988; 8: 1151-1157
- Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020; 370: m2687
- Relative adrenal insufficiency in chronic liver disease: its prevalence and effects on long-term mortality.Aliment Pharmacol Ther. 2014; 40: 819-826
- Including relative adrenal insufficiency in definition and classification of acute-on-chronic liver failure.Clin Gastroenterol Hepatol. 2020; 18: 1188-1196.e3
- Cholemic nephropathy causes acute kidney injury and is Accompanied by loss of Aquaporin 2 in Collecting Ducts.Hepatology. 2019; 69: 2107-2119
- Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.Crit Care. 2008; 12: R4
- Prognostic importance of the cause of renal failure in patients with cirrhosis.Gastroenterology. 2011; 140: 488-496.e4
- Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.Dig Dis Sci. 2012; 57: 2362-2370
- Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study.Hepatology. 2019; 70: 319-333
- Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.J Hepatol. 2012; 57: 267-273
- Increased urinary neutrophil gelatinase associated lipocalin in urinary tract infections and leukocyturia.Clin Chem Lab Med. 2011; 49: 999-1003
- Urinary interleukin 18 for Detection of acute kidney injury: a meta-analysis.Am J Kidney Dis. 2013; 62: 1058-1067
- Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis.PLoS One. 2015; 10: e0128145
- Urine interleukin 18 and lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: a systematic review and meta-analysis.Clin Gastroenterol Hepatol. 2017; 15: 1003-1013.e3
- Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.Gastroenterology. 1993; 105: 229-236
- Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites.Liver Int. 2018; 38: 1785-1792
- Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.Gastroenterology. 1988; 94: 1493-1502
- Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.Hepatology. 2012; 55: 1172-1181
- A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.Hepatology. 2005; 42: 627-634
- Albumin selectively inhibits TNFα-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells.Cardiovasc Res. 2002; 55: 820-829
- Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis.Scand J Gastroenterol. 2009; 44: 619-625
- Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis.Hepatology. 1994; 20: 1495-1501
- Primary prophylaxis of spontaneous bacterial peritonitis Delays hepatorenal syndrome and improves survival in cirrhosis.Gastroenterology. 2007; 133: 818-824
- Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol. 2017; 29: 1109-1117
- Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure.Clin Gastroenterol Hepatol. 2017; 15: 438-445.e5
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol. 2018; 69: 406-460
- Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.Am J Kidney Dis. 2011; 58: 928-938
- In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V(1) and V(2).J Exp Pharmacol. 2017; 10: 1-7
- The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions.J Clin Invest. 2004; 113: 302-309
- A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design.Open Access J Clin Trials. 2012; 4: 39-49
- Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.Gastroenterology. 2008; 134: 1352-1359
- Terlipressin and the treatment of hepatorenal syndrome: How the CONFIRM trial Moves the story Forward.Am J Kidney Dis. 2022; 79: 737-745
- Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome.New Engl J Med. 2021; 384: 818-828
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study.Hepatology. 2016; 63: 983-992
- Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.J Hepatol. 2007; 47: 499-505
- An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.Am J Gastroenterol. 2008; 103: 1689-1697
- Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.J Hepatol. 2012; 56: 1293-1298
- Acute effects of the oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.Hepatology. 1998; 28: 937-943
- Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.Hepatology. 1999; 29: 1690-1697
- Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.Hepatology. 2004; 40: 55-64
- Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.Hepatology. 2015; 62: 567-574
- Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms.Hepatology. 2013; 57: 266-276
- Antioxidant activity of albumin-bound bilirubin.Proc Natl Acad Sci. 1987; 84: 5918-5922
- Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation.Am J Respir Crit Care Med. 2000; 162: 1539-1546
- Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.Hepatology. 1998; 28: 416-422
- Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: a systematic review and meta-analysis.Dig Liver Dis. 2018; 50: 323-330
- Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin.J Crit Care. 2015; 30: 969-974
- Chances of renal recovery or liver transplantation after Hospitalization for alcoholic liver disease requiring dialysis.Dig Dis Sci. 2018; 63: 2800-2809
- Renal replacement therapy for acute kidney injury in severe alcohol-associated hepatitis as a bridge to transplant or recovery.Dig Dis Sci. 2022; 67: 697-707
- EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol. 2010; 53: 397-417
- Management of adult patients with ascites due to cirrhosis: an update.Hepatology. 2009; 49: 2087-2107
- Predicting end-stage renal disease after liver transplant.Am J Transpl. 2013; 13: 1782-1792
Organ Procurement and Transplantation Network. Policies. 2022. Available at: https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf
- Unveiling the vasodilatory actions and mechanisms of relaxin.Hypertension. 2010; 56: 2-9
- Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.Plos Med. 2017; 14: e1002248
- Treatment of type-1 hepatorenal syndrome with Pentoxifylline: a randomized placebo controlled clinical trial.Ann Hepatol. 2018; 17: 300-306
Article info
Publication history
Published online: October 17, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
